OAJ
MLNT

Ogorek Anthony Joseph’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Ogorek Anthony Joseph’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12
Closed – – 143
2018
Q1 		$0 Hold
12
– – ﹤0.01% 148
2017
Q4 		$0 Buy
+12
New +$888 ﹤0.01% 134

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ogorek Anthony Joseph's MLNT Position: Q2 2018 in Review

Ogorek Anthony Joseph sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2018, closing a stake of 12 shares.

Ogorek Anthony Joseph first reported a position in MLNT in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 87 funds tracked by Wall St. Rank hold MLNT as of Q2 2018.

  • Ogorek Anthony Joseph reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Ogorek Anthony Joseph sold 12 Melinta Therapeutics, Inc. Common Stock shares in Q2 2018.
  • Ogorek Anthony Joseph first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Ogorek Anthony Joseph's Melinta Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Ogorek Anthony Joseph's 13F filing for Q2 2018, filed 12 Jul 2018.